Medine.co.uk

Potassium Nitrate And Sodium Fluoride 5/0.315% W/W Toothpaste

Informations for option: Potassium Nitrate And Sodium Fluoride 5/0.315% W/W Toothpaste, show other option
Document: spc-doc_PL 44673-0065 change

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Potassium Nitrate and Sodium Fluoride 5/0.315% w/w Toothpaste

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Potassium Nitrate 5.0% w/w

Sodium Fluoride 0.315% w/w (1450 ppm fluoride)

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Toothpaste

Smooth, glossy, white paste, free from any undispersed or extraneous material with no more than a few air bubbles, no larger than a pin head.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Relief of dentinal hypersensitivity.

Prevention of dental caries.

Protection against the effects of acid erosion of tooth enamel. Prevention of the pain of dentinal hypersensitivity.

Ongoing protection from dentinal hypersensitivity.

4.2    Posology and method of administration

For dental use.

Use twice a day and not more than three times, in place of ordinary toothpaste. Minimise swallowing and spit out.

Not for use by children under 12 years of age unless on advice of a dental professional or doctor.

4.3    Contraindications

Known allergic reactions to any of the active ingredients or excipients.

4.4 Special warnings and precautions for use

Always follow the label directions. As with any other oral care products, if irritation occurs discontinue use.

Sensitive teeth may indicate an underlying problem which needs prompt care,, if symptoms persist or worsen see your dentist.

Keep out of the reach and sight of children.

4.5 Interaction with other medicinal products and other forms of interaction

None known

4.6 Pregnancy and lactation

No adverse effects known

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Minor local irritations. Very rarely, isolated cases of hypersensitivity type reactions such as angioedema, oral and facial swelling have been reported in patients using potassium nitrate containing toothpastes, particularly in patients who are predisposed to hypersensitivity type reactions.

4.9 Overdose

No symptoms of overdose are known

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC Code Sodium Fluoride: A01AA01

ATC Code Potassium Nitrate: Not assigned

Potassium ions are thought to reduce hypersensitivity by interfering with pulpal nerve conduction. With twice daily tooth brushing, Potassium Nitrate and Sodium Fluoride 5/0.315% w/w Toothpaste delivers the regular doses of potassium ions required to build up and then maintain its depolarising activity, thereby providing ongoing protection from, and prevention of dentinal hypersensitivity. Once regular use is discontinued, the desensitising activity of the potassium ions within the dentine tubules will slowly be lost and sensitivity pain will return.

Sodium fluoride is an established anticaries agent, which prevents dental caries. Fluoride inhibits caries and acid-erosion of dental enamel and dentine by promoting tooth remineralisation/rehardening and inhibiting tooth demineralisation/enamel softening. Fluoride in the oral cavity is incorporated into hydroxyapatite in enamel to form fluoroapatite. Fluoroapatite is less soluble than hydoxyapatite and more resistant to acid attack than the original enamel that it replaces. Fluoride also inhibits the metabolism of acid-producing bacteria which are responsible for caries.

Dental type silicas act as polishing and cleaning agents to assist in the removal of food remnants from the teeth. The grade of silica in the product provides an abrasivity level which is low relative to most other toothpastes, but is within that recommended in the International Standard ISO 11609 for dentifrice products.

5.2 Pharmacokinetic properties

The product is applied topically and so the pharmacokinetics of the active ingredients are not relevant to its efficacy.

5.3 Preclinical safety data

The active ingredients in the product are commonly used and well established. Their safety is supported by numerous published studies. Many years of clinical experience with the use of these substances in man supports the opinion that they have a favourable safety profile.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Purified Water,

Sorbitol, Liquid 70%,

Silica, Dental Type,

Glycerol,

Xanthan Gum,

Titanium Dioxide (E171),

Cocamidopropyl Betaine,

Saccharin Sodium,

Sodium Hydroxide,

Flavour Blend,

Sucralose Powder

6.2 Incompatibilities

Not applicable

6.3 Shelf life

2 Years

After opening: 6 months

6.4


Special precautions for storage

Store below 30oC


6.5


Nature and contents of container

The product will be packaged in the following containers and pack sizes:


Pack Type

Decorated, aluminium laminate tubes with a full diameter cap and with or without tamper evident nozzle seal.


Pack Size (ml) 20, 45, 75, 100


Not all pack sizes may be marketed.


6.6


Special precautions for disposal

No special precautions.


7


MARKETING AUTHORISATION HOLDER


GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom


8


MARKETING AUTHORISATION NUMBER(S)


PL 44673/0065


DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27/11/2007

10


DATE OF REVISION OF THE TEXT

06/09/2016